Sakarya University, Faculty of Medicine, Department of Medical Microbiology - Sakarya, Turkey.
Sakarya University, Faculty of Medicine, Department of Pulmonology - Sakarya, Turkey.
Rev Assoc Med Bras (1992). 2022 Feb;68(2):142-146. doi: 10.1590/1806-9282.20210745.
The vast majority of patients who hospitalized with coronavirus disease 2019 are given empirical antibiotic therapy. However, information on the frequency, microorganism species, and resistance rates of secondary bacterial infections in coronavirus disease 2019 patients are insufficient. We aimed to show the frequency of secondary infections and resistance conditions in patients with coronavirus disease 2019 hospitalized in the intensive care unit.
The results of tracheal aspirate culture, blood culture, and urine culture obtained from coronavirus disease 2019 patients - at least 2 days after their admission to the intensive care unit - were examined microbiologically.
A total of 514 patients hospitalized in intensive care unit were included in our study. Tracheal aspirate, blood, or urine cultures were collected from 369 patients (71.8%). Bacterial reproduction was detected in at least one sample in 171 (33.3%) of all patients. The rate of respiratory tract infection and/or bloodstream infection was found to be 21%. Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa in tracheal aspirate culture; Coagulase-negative staphylococci, K. pneumoniae, and A. baumannii in blood culture; and Escherichia coli, K. pneumoniae, and Enterococcus faecalis in urine culture were the most common microorganisms. A. baumannii was resistant to most antibiotics except colistin and P. aeruginosa strains were resistant to most antibiotics except amikacin, colistin, cefepime, and imipenem. In K. pneumoniae, the highest meropenem sensitivity (73%) was observed; there was a strong resistance to most of the remaining antibiotics.
We think that our study can be useful in choosing empirical antibiotic therapy in the coronavirus disease 2019 pandemic and reducing the mortality that may occur with secondary infection.
绝大多数因 2019 冠状病毒病住院的患者都接受了经验性抗生素治疗。然而,关于 2019 冠状病毒病患者继发细菌性感染的频率、微生物种类和耐药率的信息不足。我们旨在展示重症监护病房 2019 冠状病毒病患者继发感染的频率和耐药情况。
对至少在入住重症监护病房 2 天后从 2019 冠状病毒病患者获得的气管抽吸物培养物、血培养物和尿培养物的结果进行微生物学检查。
共纳入 514 例入住重症监护病房的患者。对 369 例患者(71.8%)采集了气管抽吸物、血液或尿液培养物。在所有患者中,至少有 1 份样本中检测到细菌繁殖的有 171 例(33.3%)。呼吸道感染和/或血流感染的发生率为 21%。气管抽吸物培养物中最常见的微生物为鲍曼不动杆菌、肺炎克雷伯菌和铜绿假单胞菌;血培养物中为凝固酶阴性葡萄球菌、肺炎克雷伯菌和鲍曼不动杆菌;尿培养物中为大肠埃希菌、肺炎克雷伯菌和粪肠球菌。除粘菌素外,鲍曼不动杆菌对大多数抗生素均耐药;除阿米卡星、粘菌素、头孢吡肟和亚胺培南外,铜绿假单胞菌对大多数抗生素均耐药。肺炎克雷伯菌对美罗培南的敏感性最高(73%);对其余大多数抗生素均耐药。
我们认为,我们的研究有助于在 2019 冠状病毒病大流行期间选择经验性抗生素治疗,并降低继发感染可能导致的死亡率。